Common medications that increase the risk for developing community-acquired pneumonia

Purpose of review Community-acquired pneumonia (CAP) is a common problem with significant morbidity, mortality and costs. Recent reports link several medications and the development of CAP and associated poor outcomes. Our aim was to review the most relevant data regarding the possible association of the use of inhaled corticosteroids for patients with chronic obstructive lung disease and the risk of development of CAP. In addition, we review the data regarding the use of gastric-acid suppressants including histamine-2 receptor antagonists and proton pump inhibitors and the increased incidence of CAP. Recent findings Several studies suggest inhaled corticosteroids use is associated with higher risk of CAP. In addition, the use of gastric-acid suppressants have been demonstrated to be associated with an increased risk of developing CAP. Summary We explore the potential risks, pathogenesis and implications for the healthcare system of these potential associations with the use of ICS and proton pump inhibitors and increased risk of CAP.

[1]  Claudio Pedone,et al.  Comorbidities of chronic obstructive pulmonary disease , 2011, Current opinion in pulmonary medicine.

[2]  F. Radner,et al.  Budesonide and the risk of pneumonia: a meta-analysis of individual patient data , 2009, The Lancet.

[3]  J. Castro‐Rodriguez,et al.  Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. , 2009, Chest.

[4]  S. Suissa,et al.  Inhaled corticosteroids in COPD: the case against , 2009, European Respiratory Journal.

[5]  C. Orejas,et al.  Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. , 2009, The Journal of infection.

[6]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[7]  Jiaquan Xu,et al.  Deaths: final data for 2006. , 2009, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[8]  Yoon K Loke,et al.  Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. , 2009, Archives of internal medicine.

[9]  David J Murphy,et al.  Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[10]  S. Hennessy,et al.  Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia , 2008, Annals of Internal Medicine.

[11]  M. Aseeri,et al.  Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium Difficile-Associated Diarrhea in Hospitalized Patients , 2008, The American Journal of Gastroenterology.

[12]  T. Welte,et al.  Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment , 2008, European Respiratory Journal.

[13]  R. Westendorp,et al.  Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study , 2008, Thorax.

[14]  T. Welte.  Acute exacerbation of chronic obstructive pulmonary disease: more a functional than an inflammatory problem? , 2008, American journal of respiratory and critical care medicine.

[15]  J. Maurer.  Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial , 2008 .

[16]  S. Rennard,et al.  Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. , 2008, Drugs.

[17]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[18]  A. Nogués,et al.  Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. , 2007, Respiratory medicine.

[19]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[20]  J. Hallas,et al.  Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. , 2007, Archives of internal medicine.

[21]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[23]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[24]  D. Juurlink,et al.  Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Anzueto,et al.  COPD is associated with increased mortality in patients with community-acquired pneumonia , 2006, European Respiratory Journal.

[26]  A. Torres,et al.  Mortality in COPD patients with community-acquired pneumonia: who is the third partner? , 2006, European Respiratory Journal.

[27]  J. Rello,et al.  Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia , 2006, European Respiratory Journal.

[28]  S. Suissa.  Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[29]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[30]  T. Marrie,et al.  Low-risk patients admitted with community-acquired pneumonia. , 2005, The American journal of medicine.

[31]  A. Jemal,et al.  Trends in the leading causes of death in the United States, 1970-2002. , 2005, JAMA.

[32]  D. Hoyert,et al.  Deaths: preliminary data for 2003. , 2005, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[33]  W. Thompson,et al.  The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Miriam C J M Sturkenboom,et al.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.

[35]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[36]  Dagmar Řehořková,et al.  Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. , 2004, Hepato-gastroenterology.

[37]  K. Krause,et al.  Pneumonia in the very old. , 2004, The Lancet. Infectious diseases.

[38]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[39]  M. Trabucchi,et al.  Is pneumonia still the old man's friend? , 2003, Archives of internal medicine.

[40]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[41]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[42]  S. Antoniu,et al.  Hospitalizations and mortality in the Lung Health Study , 2002, Expert review of pharmacoeconomics & outcomes research.

[43]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[44]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[45]  G. Clermont,et al.  Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. , 2002, American journal of respiratory and critical care medicine.

[46]  R. Cavallazzi,et al.  Aspiration pneumonitis and aspiration pneumonia. , 2009, The New England journal of medicine.

[47]  W. Stalman,et al.  Consultations and referrals for dyspepsia in general practice—a one year database survey , 2001, Postgraduate medical journal.

[48]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[49]  A. Corrado,et al.  Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials , 2000, BMJ : British Medical Journal.

[50]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[51]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[52]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[53]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[54]  Kerry,et al.  Trends in prescribing H2‐receptor antagonists and proton pump inhibitors in primary care , 1998, Alimentary pharmacology & therapeutics.

[55]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[56]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[57]  G. Guyatt,et al.  Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. , 1996, JAMA.

[58]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[59]  J. Vestbo,et al.  Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.

[60]  L. van Alphen,et al.  Predisposing conditions to bacterial infections in chronic obstructive pulmonary disease. , 1995, American journal of respiratory and critical care medicine.

[61]  P. Francioli,et al.  Nosocomial Pneumonia in Mechanically Ventilated Patients Receiving Antacid, Ranitidine, or Sucralfate as Prophylaxis for Stress Ulcer , 1994, Annals of Internal Medicine.

[62]  G. Bhave,et al.  Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: A randomized, controlled trial , 1992, Critical Care Medicine.

[63]  STRESS ULCER PROPHYLAXIS IN CRITICALLY ILL PATIENTS , 1989, The Lancet.

[64]  R. Jones,et al.  Prevalence of symptoms of dyspepsia in the community. , 1989, BMJ.

[65]  B. Celli,et al.  Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. , 1987, The New England journal of medicine.

[66]  R. Hunt,et al.  Relationship between gastric secretion and infection. , 1987, Gut.

[67]  S. Broitman,et al.  Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. , 1973, Annals of internal medicine.

[68]  J. Adriani,et al.  “SILENT” REGURGITATION AND ASPIRATION DURING ANESTHESIA , 1954, Anesthesiology.

[69]  L. Cancio,et al.  PIRO score for community-acquired pneumonia : A new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia To the , 2022 .